AU5690699A - Nucleoside modifications by palladium catalyzed methods - Google Patents

Nucleoside modifications by palladium catalyzed methods

Info

Publication number
AU5690699A
AU5690699A AU56906/99A AU5690699A AU5690699A AU 5690699 A AU5690699 A AU 5690699A AU 56906/99 A AU56906/99 A AU 56906/99A AU 5690699 A AU5690699 A AU 5690699A AU 5690699 A AU5690699 A AU 5690699A
Authority
AU
Australia
Prior art keywords
palladium catalyzed
nucleoside modifications
catalyzed methods
methods
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56906/99A
Other languages
English (en)
Inventor
Jeffrey T Beckvermit
Chi Tu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Publication of AU5690699A publication Critical patent/AU5690699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
AU56906/99A 1998-09-25 1999-08-20 Nucleoside modifications by palladium catalyzed methods Abandoned AU5690699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/160,747 US6020483A (en) 1998-09-25 1998-09-25 Nucleoside modifications by palladium catalyzed methods
US09160747 1998-09-25
PCT/US1999/019380 WO2000018780A1 (en) 1998-09-25 1999-08-20 Nucleoside modifications by palladium catalyzed methods

Publications (1)

Publication Number Publication Date
AU5690699A true AU5690699A (en) 2000-04-17

Family

ID=22578254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56906/99A Abandoned AU5690699A (en) 1998-09-25 1999-08-20 Nucleoside modifications by palladium catalyzed methods

Country Status (3)

Country Link
US (4) US6020483A (US06846918-20050125-C00027.png)
AU (1) AU5690699A (US06846918-20050125-C00027.png)
WO (1) WO2000018780A1 (US06846918-20050125-C00027.png)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020483A (en) * 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US7033753B1 (en) * 1999-01-15 2006-04-25 University Of Rochester Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms
CA2425605A1 (en) * 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
ES2474192T3 (es) 2001-05-25 2014-07-08 Duke University Moduladores de agentes farmacol�gicos
CA2500224C (en) * 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US7383500B2 (en) 2004-04-30 2008-06-03 Microsoft Corporation Methods and systems for building packages that contain pre-paginated documents
CN101321775B (zh) * 2005-10-03 2012-05-23 大学健康网络 用于治疗疟疾的odcase抑制剂
WO2008083465A1 (en) * 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2009102427A2 (en) * 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US8815828B2 (en) * 2008-07-02 2014-08-26 University Of Florida Research Foundation, Inc. Therapeutic combinations for use in neoplasia
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2542266A4 (en) 2010-03-03 2013-10-23 Somalogic Inc 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
US8598140B2 (en) 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
US9938314B2 (en) 2013-11-21 2018-04-10 Somalogic, Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
RU2744194C2 (ru) 2013-12-02 2021-03-03 Фио Фармасьютикалс Корп Иммунотерапия рака
EP3077050B1 (en) 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
JP2017514908A (ja) 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
EP3099079A1 (en) 2015-05-29 2016-11-30 Thomson Licensing Method for displaying, in a vehicle, a content from 4d light field data associated with a scene
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3365446A4 (en) 2015-10-19 2019-06-26 Phio Pharmaceuticals Corp. SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
JP2023501445A (ja) 2019-11-08 2023-01-18 フィオ ファーマシューティカルズ コーポレーション 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド
EP4085136A1 (en) 2019-12-31 2022-11-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
KR20240041973A (ko) 2021-08-04 2024-04-01 피오 파마슈티칼스 코프. 화학적으로 변형된 올리고뉴클레오티드

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5047519A (en) * 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US5420276A (en) * 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
JPH02215793A (ja) * 1989-02-15 1990-08-28 Yamasa Shoyu Co Ltd ヌクレオシドのアルキル化方法
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
CA2058632C (en) * 1989-06-05 2004-08-24 Brian C. Froehler Exonuclease-resistant oligonucleotides and methods for preparing the same
EP0942000B1 (en) * 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
ATE139255T1 (de) * 1989-10-24 1996-06-15 Gilead Sciences Inc Oligonukleotidanaloga mit neuartigen bindungen
DE69133405T2 (de) * 1990-01-11 2005-07-07 Isis Pharmaceutical, Inc., Carlsbad Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression
AU7759291A (en) * 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5580972A (en) * 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6020483A (en) * 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods

Also Published As

Publication number Publication date
US6020483A (en) 2000-02-01
US20020103367A1 (en) 2002-08-01
WO2000018780A1 (en) 2000-04-06
US20040034212A1 (en) 2004-02-19
US6512106B2 (en) 2003-01-28
US6355787B1 (en) 2002-03-12
US6846918B2 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
AU5690699A (en) Nucleoside modifications by palladium catalyzed methods
AU4241296A (en) Purine nucleoside modifications by palladium catalyzed methods
AU1230700A (en) Downhole activation system
AU1648300A (en) Seat
AUPP230698A0 (en) Back support
AU5282900A (en) Acoustic counter-sniper system
HK1034978A1 (en) Adenosine derivatives.
AU4026399A (en) Seat mounting mechanism
AU5820999A (en) Non-circular micro-via
AUPP725498A0 (en) Back support improvement
EP1113094A3 (en) Plating analysis method
AU1317301A (en) Silencer
AU7319900A (en) Electroless plating method
AU4053497A (en) Palladium catalyzed indolization
AU5685599A (en) Log facade
AU2001230678A1 (en) Gating system
AU5508999A (en) Mounting structure
AU2007234466B2 (en) Seating system
AU5891799A (en) Simulation system i
GB9821999D0 (en) Structural bracket
AU7019200A (en) Nucleoside analogues
AU6344599A (en) Armrest
AU3495399A (en) Back massager
AUPP412198A0 (en) Methods
AUPP408198A0 (en) Methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase